These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22500138)

  • 21. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.
    Crill WD; Hughes HR; Delorey MJ; Chang GJ
    PLoS One; 2009; 4(4):e4991. PubMed ID: 19337372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and control of influenza and dengue through vaccine development.
    Greenberg DP; Robertson CA; Gordon DM
    Pediatr Ann; 2013 Aug; 42(8):172-7. PubMed ID: 23910031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of dengue virus strains for human challenge studies.
    Mammen MP; Lyons A; Innis BL; Sun W; McKinney D; Chung RC; Eckels KH; Putnak R; Kanesa-thasan N; Scherer JM; Statler J; Asher LV; Thomas SJ; Vaughn DW
    Vaccine; 2014 Mar; 32(13):1488-94. PubMed ID: 24468542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dengue infection: a growing global health threat.
    Hemungkorn M; Thisyakorn U; Thisyakorn C
    Biosci Trends; 2007 Oct; 1(2):90-6. PubMed ID: 20103874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue Fever: Causes, Complications, and Vaccine Strategies.
    Khetarpal N; Khanna I
    J Immunol Res; 2016; 2016():6803098. PubMed ID: 27525287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.
    Tang WW; Grewal R; Shresta S
    Curr Opin Virol; 2015 Aug; 13():61-6. PubMed ID: 26001278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
    Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
    Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dengue vaccine design: issues and challenges.
    Cardosa MJ
    Br Med Bull; 1998; 54(2):395-405. PubMed ID: 9830205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue: Status of current and under-development vaccines.
    Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S
    Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.
    Chen HR; Lai YC; Yeh TM
    J Biomed Sci; 2018 Jul; 25(1):58. PubMed ID: 30037331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dengue/dengue haemorrhagic fever: history and current status.
    Gubler DJ
    Novartis Found Symp; 2006; 277():3-16; discussion 16-22, 71-3, 251-3. PubMed ID: 17319151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever.
    Zhong XL; Liao XM; Shen F; Yu HJ; Yan WS; Zhang YF; Ye JJ; Lv ZP
    FEBS Open Bio; 2019 Mar; 9(3):468-477. PubMed ID: 30868055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dengue viruses and promising envelope protein domain III-based vaccines.
    Fahimi H; Mohammadipour M; Haddad Kashani H; Parvini F; Sadeghizadeh M
    Appl Microbiol Biotechnol; 2018 Apr; 102(7):2977-2996. PubMed ID: 29470620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue vaccine development: strategies and challenges.
    Ramakrishnan L; Pillai MR; Nair RR
    Viral Immunol; 2015 Mar; 28(2):76-84. PubMed ID: 25494228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue: a global threat.
    Thisyakorn U; Thisyakorn C
    J Med Assoc Thai; 2015 Jan; 98 Suppl 1():S118-22. PubMed ID: 25764623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitation of T lymphocyte subsets helps to distinguish dengue hemorrhagic fever from classic dengue fever during the acute febrile stage.
    Fadilah SA; Sahrir S; Raymond AA; Cheong SK; Aziz JA; Sivagengei K
    Southeast Asian J Trop Med Public Health; 1999 Dec; 30(4):710-7. PubMed ID: 10928365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue vaccine development: Global and Indian scenarios.
    Swaminathan S; Khanna N
    Int J Infect Dis; 2019 Jul; 84S():S80-S86. PubMed ID: 30684747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.